Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Johnson & Johnson Dips On Q4 Earnings
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highligh
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.
US FDA approves new nasal spray for depression treatment
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
Ben Johnson Is Firing 5 Bears Coaches
Caleb Williams Screamed In Excitement When Chicago Bears Hired Ben Johnson
Chicago Bears rookie quarterback Caleb Williams has a new coach in Ben Johnson. Williams is "insanely excited" to play for Johnson and says he screamed when he found out the news. Johnson is considere
Why Ben Johnson bet on the Bears, Caleb Williams: 'He's fearless'
Caleb Williams is the biggest reason Ben Johnson took the Bears' head coaching job. Here's why Johnson is so high on the young QB.
Caleb Williams played a big role in Ben Johnson choosing the Bears
The Chicago Bears introduced Ben Johnson as their new head football coach Wednesday at Halas Hall. He was the hottest name on the market coming into the search, and his work as Detroit Lions offensive coordinator is the primary reason.
Ben Johnson takes a jab at Matt LaFleur
Ben Johnson takes a jab at Matt LaFleur during introductory news conference
Bears head coach Ben Johnson makes a joke about beating Packers coach Matt LaFleur twice a season.
Schrager: Ben Johnson Called Out Matt LaFleur Despite Having No Prior Relationship
Ben Johnson got a head start on being part of the historic rivalry between the Chicago Bears and Green Bay Packers. During his introductory press
Ben Johnson takes dig at Packers coach Matt LaFleur
Ben Johnson had his choice of several jobs. He chose the Bears. Not only do they have a quarterback to build around, but Johnson also noted they are in a division with which he is familiar. Johnson spent six seasons in the NFC North as an assistant under Dan Campbell.
Cam Johnson, NBA and Nets
NBA Rumors: Kings Not in Cam Johnson Talks, Will Aggressively Explore Trade Options
Don't expect the Sacramento Kings to swing a deal for Brooklyn Nets' wing Cam Johnson. According to NBA reporter Marc Stein, the Kings have been
Why Nets’ Cam Johnson is a coveted player as NBA trade deadline nears
Cam Johnson, the soon-to-be 29-year-old Brooklyn Nets wing, has been arguably their best player overall this season. Let’s explore what makes Johnson one of the hottest options on the trade market. Johnson is the 3-and-D prototype,
Nets’ Cam Johnson tuning out trade rumors swirling around him
Cam Johnson knows what time it is. Or more accurately, what time of year it is. With this a rebuilding year for the Nets, Johnson knew his name would come up in trade rumors. And with the Feb. 6 deadline just two weeks away,
5h
Johnson & Johnson price target lowered to $165 from $170 at Raymond James
Raymond James lowered the firm’s price target on Johnson & Johnson to $165 from $170 and keeps an Outperform rating on the shares.
1d
Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness
Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...
MarketBeat on MSN
6d
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...
6h
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
6d
on MSN
Mike Johnson has a new headache in the narrowly divided House: From the Politics Desk
Johnson sent shockwaves around Capitol Hill when he decided to oust Rep. Mike Turner, R-Ohio — a staunch NATO supporter who ...
6d
Johnson Installs Crawford on Intelligence Panel, Pulling It Closer to Trump
The speaker replaced a Republican who had criticized the president-elect and broken with him on key issues, and who had drawn ...
1d
Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond
Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback